---
title: "(NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research."
ocid: "ocds-h6vhtk-03719a"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-03719a"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-03719a.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-03719a.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "NEWCASTLE UNIVERSITY"
published: "2022-09-30"
---

# (NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research.

Buyer: NEWCASTLE UNIVERSITY  
Current stage: Award  
OCID: ocds-h6vhtk-03719a

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-03719a)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-03719a.json)

## Summary

Newcastle University has recently completed a tender process titled "(NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research" in the services category. The procurement stage was cancelled, with an award granted to Cambridge Drug Discovery. The procurement method used was a selective Restricted procedure. The tender involved the provision of consultancy services related to cancer and neurodegenerative diseases, with key phases planned from September 2022 to June 2023.

This tender provides an opportunity for businesses in the business and management consultancy services sector interested in working with universities on cutting-edge research commercialisation projects focused on oncogenes and neurodegenerative diseases. The requirements of the tender include meeting quality and price criteria as specified in the award criteria. With the involvement of universities such as Newcastle University and the University of Bath, successful bidders can not only gain financial value but also contribute to innovative research projects with potential societal impact.

## Notice

Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US$92Bn in 2019 and is expected to reach US$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US$35.5Bn Million in 2018 and is projected to reach US$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively. The initial brief of the executive will be to: Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck; Phase (2)September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board Phase (3) January 2023-March 2023 - a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University; b. Work with the Unit TT team to obtain founder academics' and University approval for appointment as CEO. c. Provide to the University of Bath all matters necessary for Research England reporting requirements. Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure seed finance, draft and submit Innovate UK proposal for preclinical funding Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.

### Lot Information

Lot 1

Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US$92Bn in 2019 and is expected to reach US$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US$35.5Bn Million in 2018 and is projected to reach US$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively. The initial brief of the executive will be to: Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck; Phase (2)September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board Phase (3) January 2023-March 2023 - a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University; b. Work with the Unit TT team to obtain founder academics' and University approval for appointment as CEO. c. Provide to the University of Bath all matters necessary for Research England reporting requirements. Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure seed finance, draft and submit Innovate UK proposal for preclinical funding Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/027417-2022 |
| Notice type | Award Notice |
| Procurement type | Dynamic |
| Procurement category | Services |
| Procurement method | Selective |
| Procurement method details | Restricted procedure |
| Tender suitability | Not specified |
| Awardee scale | SME |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 30 Sep 2022 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 20 Sep 2022 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £30,000 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NEWCASTLE UNIVERSITY |
| Additional buyers | DURHAM UNIVERSITY; EUROPEAN UNION; NORTHUMBRIA UNIVERSITY NEWCASTLE NEWCASTLE; TEESSIDE UNIVERSITY; UNIVERSITY OF BATH ON BEHALF OF THE SETSQUARED; UNIVERSITY OF SUNDERLAND |
| Locality | NEWCASTLE |
| Post town | Newcastle upon Tyne |
| Postcode | NE1 7RU |
| Country | England |
| ITL 1 | TLC North East (England) |
| ITL 2 | TLC4 Northumberland, Durham and Tyne & Wear |
| ITL 3 | TLC43 Tyneside |
| Local authority | Newcastle upon Tyne |
| Electoral ward | Monument |
| Westminster constituency | Newcastle upon Tyne Central and West |
| Delivery location | TLC North East (England) |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 1 |
| Supplier names | CAMBRIDGE DRUG DISCOVERY |

## CPV Codes

### Divisions

- 79 - Business services: law, marketing, consulting, recruitment, printing and security

### Codes

- 79400000 - Business and management consultancy and related services

## Release History

- 30 Sep 2022 at 08:41 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/027417-2022

## Notice URLs

- https://Sunderland.ac.uk
- https://northumbria.ac.uk
- https://ted.europa.eu/udl?uri=TED:NOTICE:528050-2022:TEXT:EN:HTML
- https://www.bath.ac.uk/
- https://www.durham.ac.uk
- https://www.ncl.ac.uk
- https://www.tees.ac.uk/

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-03719a. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-03719a.json.